Skip to main content
Top
Published in: BMC Immunology 1/2017

Open Access 01-12-2017 | Research article

IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: a case report

Authors: Xin-yao Wu, Yu-feng Yin, Jia-lin Teng, Li-wei Zhang, Cheng-de Yang

Published in: BMC Immunology | Issue 1/2017

Login to get access

Abstract

Background

The monoclonal gammopathies are a group of plasma-cell proliferative disorders characterized by the secretion of monoclonal immunoglobulin (M protein or paraprotein). Some rare cases have revealed the specific affinity of paraprotein as autoantibody. Here we report a patient with monoclonal gammopathy of undetermined significance (MGUS) accompanied by a remarkable increase of anticardiolipin antibody (aCL) and an extensively decreased coagulation factor activity, however, without any clinical signs of antiphospholipid syndrome (APS) and bleeding.

Results

Our further investigation indicated that IgMκ paraprotein of this patient possessed an antibody activity against phospholipids so as to bind to cardiolipin and interfere with coagulation assay in vitro.

Conclusions

This case might be indicative that an abnormality of coagulation tests, disturbed by IgMκ paraprotein, does not predict a risk of bleeding in this patient.
Literature
1.
go back to reference International Myeloma Working G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–57.CrossRef International Myeloma Working G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–57.CrossRef
2.
go back to reference Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance: a review. Immunol Rev. 2003;194:112–39.CrossRefPubMed Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance: a review. Immunol Rev. 2003;194:112–39.CrossRefPubMed
3.
go back to reference Caers J, Vekemans M-C, Bries G, Beel K, Delrieu V, Deweweire A, Demuynck H, De Prijck B, De Samblanx H, Kentos A, et al. Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. Ann Med. 2013;45(5–6):413–22.CrossRefPubMed Caers J, Vekemans M-C, Bries G, Beel K, Delrieu V, Deweweire A, Demuynck H, De Prijck B, De Samblanx H, Kentos A, et al. Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. Ann Med. 2013;45(5–6):413–22.CrossRefPubMed
4.
go back to reference Taher A, Abiad R, Uthman I. Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance. Lupus. 2003;12(11):854–6.CrossRefPubMed Taher A, Abiad R, Uthman I. Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance. Lupus. 2003;12(11):854–6.CrossRefPubMed
5.
go back to reference Sallah S, Husain A, Wan J, Vos P, Nguyen NP. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol. 2004;15(10):1490–4.CrossRefPubMed Sallah S, Husain A, Wan J, Vos P, Nguyen NP. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol. 2004;15(10):1490–4.CrossRefPubMed
6.
go back to reference Decaux O, Laurat E, Perlat A, Cazalets C, Jego P, Grosbois B. Systemic manifestations of monoclonal gammopathy. Eur J Intern Med. 2009;20(5):457–61.CrossRefPubMed Decaux O, Laurat E, Perlat A, Cazalets C, Jego P, Grosbois B. Systemic manifestations of monoclonal gammopathy. Eur J Intern Med. 2009;20(5):457–61.CrossRefPubMed
7.
go back to reference Colwell NS, Tollefsen DM, Blinder MA. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haematol. 1997;97(1):219–26.CrossRefPubMed Colwell NS, Tollefsen DM, Blinder MA. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haematol. 1997;97(1):219–26.CrossRefPubMed
8.
go back to reference Diminno G, Coraggio F, Cerbone AM, Capitanio AM, Manzo C, Spina M, Scarpato P, Dattoli GM, Mattioli PL, Mancini M. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest. 1986;77(1):157–64.CrossRefPubMedPubMedCentral Diminno G, Coraggio F, Cerbone AM, Capitanio AM, Manzo C, Spina M, Scarpato P, Dattoli GM, Mattioli PL, Mancini M. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest. 1986;77(1):157–64.CrossRefPubMedPubMedCentral
9.
10.
go back to reference von Landenberg P, Scholmerich J, Andreesen R, Vogelhuber M, Lackner KJ. A case of Waldenstroem’s disease with a monoclonal IgM antiphospholipid antibody. Rheumatol Int. 2002;22(3):129–31.CrossRef von Landenberg P, Scholmerich J, Andreesen R, Vogelhuber M, Lackner KJ. A case of Waldenstroem’s disease with a monoclonal IgM antiphospholipid antibody. Rheumatol Int. 2002;22(3):129–31.CrossRef
11.
go back to reference Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest. 1980;66(3):397–405.CrossRefPubMedPubMedCentral Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest. 1980;66(3):397–405.CrossRefPubMedPubMedCentral
12.
go back to reference Talamo G, Mir MA, Pandey MK, Sivik JK, Raheja D. IgM MGUS associated with anti-MAG neuropathy: a single institution experience. Ann Hematol. 2015;94(6):1011–6.CrossRefPubMed Talamo G, Mir MA, Pandey MK, Sivik JK, Raheja D. IgM MGUS associated with anti-MAG neuropathy: a single institution experience. Ann Hematol. 2015;94(6):1011–6.CrossRefPubMed
13.
go back to reference Forni GL, Pinto V, Musso M, Mori M, Girelli D, Caldarelli I, Borriello A, Ragione FD. Transferrin-immune complex disease: a potentially overlooked gammopathy mediated by IgM and IgG. Am J Hematol. 2013;88(12):1045–9.CrossRefPubMed Forni GL, Pinto V, Musso M, Mori M, Girelli D, Caldarelli I, Borriello A, Ragione FD. Transferrin-immune complex disease: a potentially overlooked gammopathy mediated by IgM and IgG. Am J Hematol. 2013;88(12):1045–9.CrossRefPubMed
14.
go back to reference Riksen NP, Luken BM, Klasen IS, Voorberg J, Crama N, van Deuren M. Antibodies against the CUB1-2 domains of ADAMTS13 in a patient with benign monoclonal gammopathy: no causal relationship. Haematologica. 2007;92(7):e74–6.CrossRefPubMed Riksen NP, Luken BM, Klasen IS, Voorberg J, Crama N, van Deuren M. Antibodies against the CUB1-2 domains of ADAMTS13 in a patient with benign monoclonal gammopathy: no causal relationship. Haematologica. 2007;92(7):e74–6.CrossRefPubMed
15.
go back to reference Konrad RJ, Kricka LJ, Goodman DB, Goldman J, Silberstein LE. Brief report: myeloma-associated paraprotein directed against the HIV-1 p24 antigen in an HIV-1-seropositive patient. N Engl J Med. 1993;328(25):1817–9.CrossRefPubMed Konrad RJ, Kricka LJ, Goodman DB, Goldman J, Silberstein LE. Brief report: myeloma-associated paraprotein directed against the HIV-1 p24 antigen in an HIV-1-seropositive patient. N Engl J Med. 1993;328(25):1817–9.CrossRefPubMed
Metadata
Title
IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: a case report
Authors
Xin-yao Wu
Yu-feng Yin
Jia-lin Teng
Li-wei Zhang
Cheng-de Yang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2017
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/s12865-017-0213-0

Other articles of this Issue 1/2017

BMC Immunology 1/2017 Go to the issue